The pharmaceutical company at the center of the EpiPen price-gouging controversy has decided to lower the cost of its medication for some patients.
Mylan, which had hiked the price of the medication by more than 400 percent, announced plans to cover up to $300 — or roughly 50 percent — of the cost of a pack of two EpiPens for patients who were paying the full amount.
The company also plans to double the eligibility for its patient assistance program, which will eliminate out-of-pocket costs for uninsured and under-insured patients and families.
Mylan CEO Heather Bresch said in a statement, "We ... are taking immediate action to help ensure that everyone who needs an EpiPen ... gets one."
Mylan pointed part of the blame on the price hike on the insurance industry, which is becoming a common defense for the pharmaceutical industry.
More patients and families have enrolled in high-deductible health plans due in part to the Affordable Care Act and this has led to "higher costs for their medicine," the company said.
Bresch is the daughter of West Virginia Democratic Sen. Joe Manchin. According to Bloomberg, Manchin has been silent on the issue.
Lawmakers called for hearings following the price hike of the allergy medication.
Hillary Clinton on Wednesday slammed the price hike and said it's wrong when "drug companies put profits ahead of patients, raising prices without justifying the value behind them."
White House press secretary Josh Earnest refused to criticize the company for the price hike. "I'm not going to make specific comment or specifically second-guess the pricing strategy or the business practices of one private enterprise," he said Wednesday.
He said companies "do real damage to their reputation by being greedy and jacking up prices in a way that victimizes vulnerable Americans. … It raises signification questions" in people's minds.
The EpiPen price hike is the latest to spark outrage from lawmakers and the public against the pharmaceutical industry. Lawmakers have been angry with Gilead Science's hepatitis C cure Sovaldi, which cost $1,000 per pill when it was first approved a few years ago.
Last year, a small biotech firm called Turing Pharmaceuticals raised the price of an anti-malarial drug Daraprim by 5,000 percent. The price hike, and social media antics of former CEO Martin Shkreli, fueled a fierce public backlash.
Robert King contributed to this report.